Testing an oral medication for hemophilia A
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests an experimental oral medication (Inno8) for people with hemophilia A. It aims to find the best dose and see how the body handles it. You may be able to join if you have mild to severe hemophilia A and are not on other preventive treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male and between 18 and 64 years old.
- You weigh at least 99 pounds (45 kg).
- You have hemophilia A with factor VIII activity of 15% or less (mild to severe), with or without inhibitors.
- You have not used any preventive hemophilia A treatment within a certain timeframe before the study starts.
- You do not have a high risk of blood clots (like a personal or family history of deep vein thrombosis).
- You do not have other bleeding disorders besides hemophilia A.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well and how safely Octapharma’s clotting factor products (Nuwiq, Octanate, or Wilate) work in people with Hemophilia A who are newly treated or have had very few clotting factor doses. It also looks at how often side effects occur and how the treatments are used in real care.
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This trial tests a single dose of ANB-002, an experimental therapy for hemophilia B. It aims to see if the drug is safe and effective for people with severe hemophilia B who have been treated with factor IX before and do not have inhibitors.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This trial tests a new factor VIII treatment (SKP-0141) for severe hemophilia A. It aims to see if it can prevent or treat bleeding episodes, replacing standard factor VIII therapy.
Hear when a new Haemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.